This ExpertREACT article was originally published on 12 January 2009. Policy data and programme statuses described reflect the state of knowledge at that date.
Three pandemics in the twentieth century: a lesson not forgotten
Influenza pandemics - caused by new subtypes of influenza A spreading in populations with little or no pre-existing immunity - represent one of the most serious threats to global human health. The twentieth century witnessed three significant pandemics: 1918 (A/H1N1 Spanish flu), 1957 (A/H2N2) and 1968 (A/H3N2). Each was associated with high clinical attack rates of 25-35% and elevated case fatality rates, with the 1918 pandemic alone estimated to have killed 50-100 million people. Even a "mild" pandemic similar to those of 1957 and 1968 could kill millions in today's more populous and connected world.
President Bush's November 2005 National Strategy for Pandemic Influenza mobilised $7.1bn in HHS budget authority, of which approximately $4bn was allocated to vaccine-related activities: production capacity expansion, stockpile building and investment in cell-based expression systems to move beyond egg-dependent manufacturing. As of December 2008, 67 countries had confirmed H5N1 in animals - a dramatic increase from 11 countries in 2004 - reinforcing the need for ongoing preparedness. HHS Secretary Levitt's January 2009 update confirmed substantial progress: antigen stockpile expansion, multiple cell-based vaccine manufacture clinical trial completions, and advances in adjuvant-based dose-sparing approaches.
Cell-based capacity and the priming debate
A central theme of the US pandemic plan was accelerating the transition from egg-based to cell-based influenza vaccine manufacturing, which would substantially reduce lead times for pandemic vaccine production. Multiple cell-based clinical trials had been completed by early 2009, though none of the cell-derived vaccines had yet achieved US licensure for seasonal use - a prerequisite for any pandemic deployment. The update also addressed the ongoing expert debate around pre-emptive priming strategies - providing populations with H5N1 antigen in advance to prime immune memory - as a complement to reactive vaccine strategies. VacZine Analytics viewed the HHS update as a positive signal that vaccine preparedness infrastructure was meaningfully advancing, even if critical technology transitions remained incomplete.